The extended coverage program, CMS confirmed, will extend through December 31, 2027
We aim to hasten the transformation of sick care to true health care, to replace one-size-fits-all disease management with personalized, preventive medicine
Key Features Next-generation investigational peptide with triple receptor agonist activity Interacts with GLP-1, GIP, and glucagon receptor pathways in research models Manufactured under rigorous quality control standards for research use Supplied as a lyophilized powder for enhanced stability and storage Applications Metabolic pathway and receptor signaling research Experimental studies related to obesity and metabolic disorders Research involving glucose regulation and lipid metabolism mechanisms Advanced laboratory investigation of multi-receptor peptide activity All applications are strictly limited to laboratory research use only
All medications come from licensed 503A compounding pharmacies, and your prescription can be filled within 2 to 3 business days
During the taper, close monitoring is essential
Gastrointestinal hormones regulating appetite